Pathogenic MSH2 variants have a higher risk of prostate cancer with increasing age (23.8% cumulative incidence of PCa by age 75 years versus 13.8% for MLH1, 8.9% for MSH6, and 4.6% for PMS2) [39]. This evidence concerns the gene MSH2 and posterior cortical atrophy.